ESMO Immuno-Oncology 2022 | OpACIN-neo: TMB and IFN-γ identified as biomarkers of pathologic response in melanoma

Irene Reijers, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments on findings from a biomarker analysis of the Phase II OpACIN-neo trial (NCT02977052), which assessed ipilimumab and nivolumab in stage III melanoma. High tumor mutational burden (TMB) and high interferon-gamma (IFN-γ) were both independently identified as biomarkers associated with pathologic response. A higher TMB was linked to improved major pathologic response, but did not affect 2-year event-free survival (EFS), whereas a higher IFN-γ was linked to better EFS. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.